Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost GPs in England cannot currently prescribe Mounjaro for weight loss through the NHS — not because they don't want to, but because NHS access follows a strict phased rollout tied to BMI thresholds and specific health conditions that most people won't yet meet. Mounjaro (tirzepatide) is a prescription-only medicine; whether any doctor prescribes it depends entirely on whether you meet the clinical criteria they're working within. Private prescribers operate under the licensed eligibility criteria directly, so the route matters as much as the medicine. Read a full overview of Mounjaro in the UK to understand what treatment involves before deciding which path suits you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common assumption people bring to this question is that GPs are gatekeeping Mounjaro by choice. In most cases that's not accurate. From April 2026, GP practices in England gained the option to prescribe tirzepatide under a new contract arrangement, but the word 'option' is doing a lot of work there. Participation is voluntary, not universal, and the NHS eligibility criteria are deliberately tight. The current NHS cohort requires a BMI of 40 or above combined with four or more specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes). A second cohort covering BMI 35-39.9 with four or more of those conditions opened in June 2026. So if your GP says they can't prescribe Mounjaro right now, they're almost certainly correct for NHS purposes, not obstructing you. See the full NHS Mounjaro prescribing criteria for where the phased rollout currently stands, including planned future cohorts.
The NHS rollout is also described in detail in NICE's technology appraisal TA1026, which sets out the eligibility requirements and the phased implementation schedule.
Outside the NHS, a licensed private prescriber works directly from the medicine's authorised criteria. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as hypertension, prediabetes, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. That's a meaningfully wider group than the current NHS cohort, and there's no waiting list.
Critically, meeting the BMI number is not enough on its own. A prescriber reviews your full picture: medical history, current medicines, conditions that might contraindicate treatment, and whether your goals are realistic alongside a reduced-calorie diet and increased activity. Certain situations (including pregnancy, breastfeeding, trying to conceive, or a history of medullary thyroid carcinoma) mean Mounjaro is not appropriate regardless of BMI. The prescriber makes that call; the eligibility figures are a starting point, not an automatic green light. For more on how clinical suitability is assessed, this page covers what doctors weigh up when considering a Mounjaro prescription.
It's also worth knowing that Mounjaro's list price in the UK rose sharply from September 2025. The background to that price change is useful context if cost is part of your decision.
If your GP has said no, or if you'd rather not wait for NHS availability, a regulated private pharmacy is the other legal route. At nume, the process starts with a free online consultation, straightforward questions about your health, medicines and history. A GPhC-registered Independent Prescriber then reads your answers personally and makes the clinical decision the same day. Not software; a real clinician who can approve, decline or ask follow-up questions.
If treatment is clinically suitable and you order before midday, your prescription is dispatched the same working day. What arrives is a plain, unbranded box via DPD with tracking, containing your Mounjaro KwikPen, each pen delivers four once-weekly doses, starting at 2.5mg to help your system settle before titration. Our clinical team's approach means the same standard of review applies to every repeat order, not just the first.
Struggling to find stock? Current Mounjaro availability in the UK is something our team monitors and can advise on at consultation.
Some GPs are keen to prescribe Mounjaro but are unfamiliar with the private route or are waiting for local NHS guidance to catch up. That's a reasonable position, tirzepatide is still a relatively new medicine carrying a Black Triangle designation, which means the MHRA requires additional post-marketing monitoring. If your GP is open to prescribing privately, there's guidance on what UK doctors can prescribe outside the NHS that may help that conversation.
Alternatively, if you'd rather not navigate the GP route at all, buying Mounjaro through a regulated online pharmacy is the option most people use. The NHS tirzepatide guidance from NHS England covers what wraparound care looks like alongside treatment, worth reading whether you go private or NHS. A short sentence worth remembering: a prescription is the process, not the obstacle.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.